RT Journal Article
SR Electronic
T1 New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 70
OP 72
DO 10.3899/jrheum.150641
VO 93
A1 Alberto Cauli
A1 Matteo Piga
A1 Ennio Lubrano
A1 Antonio Marchesoni
A1 Alberto Floris
A1 Alessandro Mathieu
YR 2015
UL http://www.jrheum.org/content/93/70.abstract
AB The pathogenesis of psoriatic arthritis (PsA) is still under discussion but great advances have been made in the last 2 decades that confirm the central role of tumor necrosis factor-α (TNF-α) in its inflammatory milieu. New therapeutic approaches have been proposed, and new molecules with anti-TNF-α activity have been chemically altered to improve their pharmacological properties. Certolizumab pegol (CZP) is a PEGylated Fc-free anti-TNF that has been shown clinically to be effective in the treatment of rheumatoid arthritis (RA), skin psoriasis, and PsA. This article summarizes available data on its clinical efficacy and safety profile in the treatment of patients with PsA.